Upstream Bio (UPB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.2M

Revenue (quarter)

$773,000.00

Revenue growth (year over year)

−17.50%

Gross profit (trailing twelve months)

$3.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$156.5M

Net income (quarter)

−$39.7M

Net income growth (year over year)

+0.66%

Net margin

−4955.67%

Return on equity

−46.05%

EPS (trailing twelve months)

−$2.88

Book value per share

$4.95

P/E (trailing twelve months)

—

Price to book

0.68

Debt to assets

3.63%

Payout ratio

—

Dividend yield

—

Company profile

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

• Is Upstream Bio (UPB) profitable?

  No. Upstream Bio reported a net loss of $156.5M over the trailing twelve months.

• How much revenue does Upstream Bio (UPB) make?

  Upstream Bio generated $3.2M in revenue over the trailing twelve months, down 17.50% year over year.

• How do I buy stock in Upstream Bio (UPB)?

  UPB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.